

1 **Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1,**
2 **BA.4 and BA.5 to therapeutic monoclonal antibodies**

3

4 Daichi Yamasoba, Ph.D.^{1,2#}, Yusuke Kosugi, M.S.^{1#}, Izumi Kimura, Ph.D.^{1#}, Shigeru
5 Fujita, D.V.M.¹, Keiya Uriu, M.S.¹, Jumpei Ito, D.V.M., Ph.D.¹, Kei Sato, Ph.D.^{1*}, The
6 Genotype to Phenotype Japan (G2P-Japan) Consortium

7

8 ¹ The University of Tokyo, Tokyo, Japan

9 ² Kobe University, Hyogo, Japan

10 # Dr. Yamasoba, Mr. Kosugi and Dr. Kimura contributed equally to this letter.

11 *Correspondence: KeiSato@g.ecc.u-tokyo.ac.jp (Kei Sato)

12

13 **Conflict of interest:** The authors declare that no competing interests exist.

14 **Word count:** 393/400 words

15

16 **Abstract**

17 As of May 2022, Omicron BA.2 variant is the most dominant variant in the world.
18 Thereafter, Omicron subvariants have emerged and some of them began
19 outcompeting BA.2 in multiple countries. For instance, Omicron BA.2.11, BA.2.12.1
20 and BA.4/5 subvariants are becoming dominant in France, the USA and South Africa,
21 respectively. In this study, we evaluated the sensitivity of these new Omicron
22 subvariants (BA.2.11, BA.2.12.1 and BA.4/5) to eight therapeutic monoclonal
23 antibodies (bamlanivimab, bebtelovimab, casirivimab, cilgavimab, etesevimab,
24 imdevimab, sotrovimab and tixagevimab). Notably, we showed that although
25 cilgavimab is antiviral against BA.2, BA.4/5 exhibits higher resistance to this antibody
26 compared to BA.2. Since mutations are accumulated in the spike proteins of newly
27 emerging SARS-CoV-2 variants, we suggest the importance of rapid evaluation of
28 the efficiency of therapeutic monoclonal antibodies against novel SARS-CoV-2
29 variants.

30 **Text**

31 During the current pandemic, severe acute respiratory syndrome coronavirus 2
32 (SARS-CoV-2) has considerably diversified. The Omicron variant was identified at
33 the end of November 2021 and rapidly spread worldwide. As of May 2022, Omicron
34 BA.2 variant is the most dominant variant in the world. Thereafter, Omicron
35 subvariants have emerged and some of them began outcompeting BA.2 in multiple
36 countries. For instance, Omicron BA.2.11, BA.2.12.1 and BA.4/5 subvariants are
37 becoming dominant in France, the USA and South Africa, respectively (**Figure 1A**).

38 Newly emerging SARS-CoV-2 variants need to be carefully monitored for
39 a potential increase in transmission rate, pathogenicity and/or resistance to immune
40 responses. The resistance of variants to vaccines and therapeutic antibodies can be
41 attributed to a variety of mutations in the viral spike (S) protein. Although the S
42 proteins of new Omicron subvariants (BA.2.11, BA.2.12.1 and BA.4/5) are based on
43 the BA.2 S, the majority of them additionally bear the following substitutions in the
44 S: BA.2.11, L452R; BA.2.12.1, L452Q and S704L; and BA.4/5, L452R, HV69-70del,
45 F486V and R493Q (**Figure 1B**). In particular, the L452R and L452Q substitutions
46 were detected in Delta and Lambda variants, and we demonstrated that the L452R/Q
47 substitution affects the sensitivity to vaccine-induced neutralizing antibodies.^{1,2}
48 Therefore, it is reasonable to assume that these new Omicron subvariants reduces
49 sensitivity towards therapeutic monoclonal antibodies. To address this possibility,
50 we generated pseudoviruses harboring the S proteins of these Omicron subvariants
51 and derivatives and prepared eight therapeutic monoclonal antibodies. Consistent
52 with previous studies,³⁻⁵ bamlanivimab, casirivimab, etesevimab, imdevimab and
53 tixagevimab were not functional against BA.2 (**Figure 1C**). These five antibodies did
54 not work against new Omicron subvariants, while the BA.2 S bearing R493Q
55 substitution was partially sensitive to casirivimab and tixagevimab (**Figure 1C** and
56 **Figure S1**). Interestingly, bebtelovimab was ~2-fold more effective against BA.2 and
57 all Omicron subvariants tested than the parental virus (**Figure 1C**). Although
58 sotrovimab was ~20-fold less antiviral against BA.2 than the parental virus, the
59 Omicron subvariants bearing L452R substitution including BA.2.11 and BA.4/5 were
60 more sensitive to sotrovimab than BA.2 (**Figure 1C**). Cilgavimab was also antiviral
61 against BA.2, while the L452R/Q substitution rendered ~2-5-fold resistance to this
62 antibody. Notably, BA.4/5 exhibited ~30-fold more resistance to cilgavimab
63 compared to BA.2 (**Figure 1C**).

64 Since mutations are accumulated in the S proteins of newly emerging
65 SARS-CoV-2 variants, we suggest the importance of rapid evaluation of the
66 efficiency of therapeutic monoclonal antibodies against novel SARS-CoV-2 variants.


67 **Grants**

68 Supported in part by AMED Research Program on Emerging and Re-emerging
69 Infectious Diseases 20fk0108146 (to Kei Sato), 20fk0108270 (to Kei Sato),
70 20fk0108413 (to Kei Sato) and 20fk0108451 (to G2P-Japan Consortium and Kei
71 Sato); AMED Research Program on HIV/AIDS 21fk0410039 (to Kei Sato); JST
72 SICORP (e-ASIA) JPMJSC20U1 (to Kei Sato); JST SICORP JPMJSC21U5 (to Kei
73 Sato), JST CREST JPMJCR20H4 (to Kei Sato); JSPS KAKENHI Grants-in-Aid for
74 Scientific Research B 18H02662 (to Kei Sato) and 21H02737 (to Kei Sato); JSPS
75 Fund for the Promotion of Joint International Research (Fostering Joint International
76 Research) 18KK0447 (to Kei Sato); JSPS Core-to-Core Program
77 JPJSCCA20190008 (A. Advanced Research Networks) (to Kei Sato); JSPS
78 Research Fellow DC1 19J20488 (to Izumi Kimura) and 22J11578 (to Keiya Uriu);
79 The Tokyo Biochemical Research Foundation (to Kei Sato); and Joint
80 Usage/Research Center program of Institute for Frontier Life and Medical Sciences,
81 Kyoto University (to Kei Sato).

82

83 **References**

- 84 1. Ferreira I, Kemp SA, Datir R, et al. SARS-CoV-2 B.1.617 mutations L452R
85 and E484Q are not synergistic for antibody evasion. *J Infect Dis*
86 2021;224(6):989-994. DOI: 10.1093/infdis/jiab368.
- 87 2. Kimura I, Kosugi Y, Wu J, et al. The SARS-CoV-2 Lambda variant exhibits
88 enhanced infectivity and immune resistance. *Cell Rep* 2022;38(2):110218.
89 DOI: 10.1016/j.celrep.2021.110218.
- 90 3. Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2
91 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal
92 antibodies. *Nat Med* 2022. DOI: 10.1038/s41591-022-01792-5.
- 93 4. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antiviral Agents
94 against the SARS-CoV-2 Omicron Subvariant BA.2. *N Engl J Med*
95 2022;386(15):1475-1477. DOI: 10.1056/NEJMc2201933.
- 96 5. Case JB, Mackin S, Errico J, et al. Resilience of S309 and AZD7442
97 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron
98 lineage strains. *BioRxiv* 2022:doi: <https://doi.org/10.1101/2022.03.17.484787>.
99



100

101 **Figure 1. Sensitivity of new Omicron subvariants to eight therapeutic**
 102 **monoclonal antibodies.**

103 (A) Epidemics of SARS-CoV-2 lineages in in France, the USA and South Africa. The
 104 data from January 13, 2022 to April 22, 2022 (100 days) for France, the USA and
 105 South Africa were analyzed. In this figure, the SARS-CoV-2 lineages other than
 106 Delta and Omicron are shown as “others”.

107 (B) Amino acid substitutions in S. Heatmap shows the frequency of amino acid
 108 substitutions in BA.2.11, BA.2.12.1, BA.4, and BA.5 compared to BA.2. Substitutions
 109 detected in >50% of sequences of any lineage are shown.

110 (C) Virus neutralization assays. A neutralization assay was performed using
 111 pseudoviruses harboring the SARS-CoV-2 S proteins of Omicron subvariants
 112 [BA.2.11 (BA.2 S:L452R), BA.2.12.1 (BA.2 S:L452Q/S704L) and BA.4/5 (BA.2 S:
 113 HV69-70del/L452R/F486V/R493Q)], their derivatives (the BA.2 S bearing L452Q,
 114 S704L, HV69-70del, F486V or R493Q, respectively) or the D614G-harboring B.1.1
 115 lineage virus (parental virus). Eight therapeutic monoclonal antibodies
 116 (bamlanivimab, bebtelovimab, casirivimab, cilgavimab, etesevimab, imdevimab,
 117 sotrovimab and tixagevimab) were tested. The assay of each antibody was
 118 performed in sextuplicate at each concentration to determine the 50% neutralization
 119 concentration. The log₂ fold changes of resistance versus the parental virus (circle
 120 size) or BA.2 (color) are respectively shown. Representative neutralization curves
 121 are shown in **Figure S1** in the Supplementary Appendix.